Product name as reported
Xigris: adverse event reports filed with FDA
1,649 reports list it as a suspect or interacting product, 2004–2015.
- 1,649
- reports as suspect product
- 0% of all reports · about 73 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 96.3%
- marked serious by the reporter
- 57.4% across all reports
- 56.9%
- record death among outcomes, as reported
- 939 reports · not verified by FDA
Between January 2004 and July 2015, 1,649 adverse event reports received by FDA list the product name "Xigris" as reporters wrote it as a suspect or interacting product. Reports that mention it only as a concomitant medication (38) are left out of every figure here.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 73 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are death (14.7%), platelet count decreased (12.5%) and thrombocytopenia (10.6%). A report can list several reactions, so shares add to more than 100%; 257 different terms appear across these reports. Death is recorded in 14.7% of these reports, against 4.1% of all reports in the database.
96.3% of the reports are marked serious by the reporter; 56.9% record death among the outcomes and 24% record hospitalisation, as reported. 60.3% of the reports came from physicians, and the largest patient age group is 45 to 64 (31.2%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
No report listing Xigris was received in the five years to June 2026; the latest was received in July 2015.
By year received
Reactions recorded in the reports
share of Xigris reports recording the termall reports in the database
- Deaththe patient died; cause not stated by this term14.7%243
- Platelet count decreasedlow platelet count12.5%206
- Thrombocytopenialow platelets10.6%175
- Activated partial thromboplastin time prolonged7.9%131
- Haemorrhagebleeding7.9%130
- Multi-organ failure7.9%130
- International normalised ratio increasedblood clotting slower than intended (raised INR)7.3%120
- Sepsisa severe body-wide response to infection6.7%111
- Haemorrhage intracranial6.2%103
- Septic shockshock arising from infection5.2%86
- Cardiac arrestthe heart stopped4.3%71
- Haemoglobin decreasedlow haemoglobin4.3%71
- Gastrointestinal haemorrhagebleeding in the stomach or bowel4.1%67
- Cerebral haemorrhage3.6%60
- Hypotensionlow blood pressure3.1%51
- General physical health deteriorationgeneral decline in health2.5%42
- Condition aggravatedthe condition being treated got worse2.3%38
- Renal failurekidney failure2.3%38
- Respiratory failurethe lungs could not supply enough oxygen2.3%38
- Medication errora mistake in prescribing, dispensing or taking a medicine1.9%31
- Pneumonialung infection1.6%26
- Pulmonary haemorrhage1.5%25
- Accidental overdosean accidental overdose1.5%24
- Epistaxisnosebleed1.5%24
- Subarachnoid haemorrhage1.5%24
- Catheter site haemorrhage1.4%23
- Haemodialysis1.4%23
Top 30 of 257 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 35.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Sepsis | 874 | 53% |
| Septic shock | 193 | 11.7% |
| Multi-organ failure | 61 | 3.7% |
| Pneumonia | 24 | 1.5% |
| Urosepsis | 20 | 1.2% |
| Abdominal sepsis | 13 | 0.8% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,649 reports.
In context
| Measure | Xigris | All reports |
|---|---|---|
| Reports as suspect product | 1,649 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 96.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 569 | 91 |
| Hospitalisation recorded, per 1,000 reports | 240 | 213 |
| Consumer-filed share | 12.7% | 45.8% |
| Top term, share of reports | Death 14.7% | 4.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Xigris reports
How many adverse event reports has FDA received for Xigris?
1,649 reports list Xigris as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 38 list it only as a concomitant medication.
What reactions are recorded in Xigris reports?
death (14.7%), platelet count decreased (12.5%), thrombocytopenia (10.6%), activated partial thromboplastin time prolonged (7.9%) and haemorrhage (7.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Xigris was responsible.
How serious are the reports?
96.3% are marked serious by the reporter. Among the outcomes recorded, 56.9% of reports include death and 24% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (60.3%), pharmacist (15%) and consumer or non-health professional (12.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Xigris rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Xigris was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Xigris?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Xigris as a suspect or interacting product; reports listing it only as a concomitant medication (38) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.